Master of Science
Department or Program
Clinical Laboratory Sciences
Department or Program Chair
Mary Sevigny, Ph.D.
Roberta M. Madej
Maria C. DeSousa, J.D., M.P.A., C.L.S.
KRAS is a proto-oncogene which was first identified in Kirsten rat sarcoma virus. The normal KRAS protein performs an essential function in normal tissue signaling and a mutation of a KRAS gene is an essential step in the development of many cancers. Q-Clamp® KRAS codon specific mutation test is an in vitro real-time qualitative PCR assay for the detection of mutations in the targeted regions and KRAS mutation often serves as a useful marker in drug response. The Q-Clamp® KRAS codon specific mutation test experiment was performed using cell-free extracted DNA (cfDNA) instead of FFPE extracted DNA. The results of the experiment showed a clear difference in the Ct’s between the mutant and internal control. Since the delta Ct’s can be discriminated, the assay showed a positive feasibility of using a cfDNA in the Q-Clamp ® KRAS codon specific mutation test.
Garcia, Manuel, "Determination of the Feasibility of Using Cell-Free DNA (cfDNA) in the Q-Clamp KRAS Codon Specific Mutation Test" (2018). Master's Theses and Capstone Projects. 335.